Under the terms of the agreement, Genomatica will provide DSM, a Dutch chemical and biotechnology firm, with its metabolic modeling and simulation technologies.
The pact builds on an earlier agreement between the two companies, and includes research and development support, technology license fees, and milestone payments. Financial details were not disclosed.
Christophe Schilling, president and chief scientific officer at Genomatica, said in a statement that the company will provide integrated metabolic engineering solutions to DSM "for developing next-generation microbial bio-factories to produce valuable industrial products from sustainable feedstocks."
DSM sells ingredients based on fermentation and enzyme technology to the chemical, pharmaceutical, and food industries.